{"id":"https://openalex.org/W3203034670","doi":"https://doi.org/10.1007/s11523-021-00839-w","title":"Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC","display_name":"Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC","publication_year":2021,"publication_date":"2021-09-01","ids":{"openalex":"https://openalex.org/W3203034670","doi":"https://doi.org/10.1007/s11523-021-00839-w","mag":"3203034670","pmid":"https://pubmed.ncbi.nlm.nih.gov/34564820","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8536603"},"language":"en","primary_location":{"id":"doi:10.1007/s11523-021-00839-w","doi":"https://doi.org/10.1007/s11523-021-00839-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00839-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00839-w.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00839-w.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047338174","display_name":"Yvette N. Lamb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115663","display_name":"Springer Nature (New Zealand)","ror":"https://ror.org/029zamy29","country_code":"NZ","type":"company","lineage":["https://openalex.org/I1313014049","https://openalex.org/I4210112888","https://openalex.org/I4210115663"]}],"countries":["NZ"],"is_corresponding":true,"raw_author_name":"Yvette N. Lamb","raw_affiliation_strings":["Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com","Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com","institution_ids":["https://openalex.org/I4210115663"]},{"raw_affiliation_string":"Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand","institution_ids":["https://openalex.org/I4210115663"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5047338174"],"corresponding_institution_ids":["https://openalex.org/I4210115663"],"apc_list":{"value":3860,"currency":"USD","value_usd":3860},"apc_paid":{"value":3860,"currency":"USD","value_usd":3860},"fwci":1.2623,"has_fulltext":true,"cited_by_count":75,"citation_normalized_percentile":{"value":0.80250064,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"16","issue":"5","first_page":"687","last_page":"695"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.8970000147819519},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9269999861717224},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7310000061988831},{"id":"https://openalex.org/keywords/flaura-trial","display_name":"FLAURA trial","score":0.8550000190734863},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.796999990940094},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9120000004768372},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8859999775886536},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7829999923706055},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.7519999742507935}],"concepts":[{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9767624735832214},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8774988651275635},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.7070767283439636},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6403639912605286},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6196016669273376},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6183112859725952},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4450753629207611},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.442034512758255},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4344823956489563},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.3535480797290802},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3323667049407959},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3102591037750244},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2842256724834442}],"mesh":[{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s11523-021-00839-w","doi":"https://doi.org/10.1007/s11523-021-00839-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00839-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00839-w.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:7441607","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC8536603","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmid:34564820","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34564820","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8536603","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8536603/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Target Oncol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s11523-021-00839-w","doi":"https://doi.org/10.1007/s11523-021-00839-w","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00839-w","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00839-w.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3203034670.pdf","grobid_xml":"https://content.openalex.org/works/W3203034670.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W1518930887","https://openalex.org/W1573292320","https://openalex.org/W1999130958","https://openalex.org/W2041835001","https://openalex.org/W2088540000","https://openalex.org/W2102748761","https://openalex.org/W2163351155","https://openalex.org/W2280175247","https://openalex.org/W2339922740","https://openalex.org/W2413097448","https://openalex.org/W2494292000","https://openalex.org/W2530508394","https://openalex.org/W2735114053","https://openalex.org/W2747965175","https://openalex.org/W2768998109","https://openalex.org/W2770828094","https://openalex.org/W2792692302","https://openalex.org/W2888877308","https://openalex.org/W2890155867","https://openalex.org/W2898171786","https://openalex.org/W2903043657","https://openalex.org/W2915706453","https://openalex.org/W2969903907","https://openalex.org/W2979271184","https://openalex.org/W2990041408","https://openalex.org/W2995595042","https://openalex.org/W2995864319","https://openalex.org/W2996433778","https://openalex.org/W3003499321","https://openalex.org/W3033600082","https://openalex.org/W3091781059","https://openalex.org/W3116112050","https://openalex.org/W3128870202","https://openalex.org/W3139019175","https://openalex.org/W3155388144","https://openalex.org/W3166198920","https://openalex.org/W4210992155","https://openalex.org/W4211193262","https://openalex.org/W4252867417"],"related_works":["https://openalex.org/W2807214711","https://openalex.org/W2842012826","https://openalex.org/W2794833946","https://openalex.org/W7212301209","https://openalex.org/W4403853600","https://openalex.org/W3128870202","https://openalex.org/W4388088436","https://openalex.org/W3120273950","https://openalex.org/W4283021180","https://openalex.org/W2286158735"],"abstract_inverted_index":{"Activating":[0],"mutations":[1,172],"in":[2,71,89,130,173,192],"the":[3,40,51,104,145,174,202,241,250],"epidermal":[4,175],"growth":[5,176],"factor":[6,177],"receptor":[7,178],"(EGFR)":[8,179],"gene":[9,180],"have":[10],"been":[11],"identified":[12],"as":[13],"key":[14],"oncogenic":[15],"drivers":[16],"of":[17,43,106,117,149,162,167,243,249],"non-small":[18],"cell":[19,140],"lung":[20,141,150],"cancer":[21,142,151],"(NSCLC).":[22],"Osimertinib":[23,80,97,122,199,253],"(Tagrisso\u00ae)":[24,200],"is":[25,36,144,153,201,254],"an":[26,255],"orally":[27],"administered,":[28],"third-generation":[29,205],"EGFR":[30,48,76,135,184,197,214,264],"tyrosine":[31,185],"kinase":[32,186],"inhibitor":[33],"(EGFR-TKI)":[34],"that":[35,248],"widely":[37],"approved":[38,204],"for":[39,128,259],"first-line":[41],"treatment":[42,115,258],"advanced":[44,78,137,216,266],"NSCLC":[45,195],"with":[46,73,91,132,155,170,194,211,261],"activating":[47],"mutations.":[49,198],"In":[50,159],"pivotal":[52],"phase":[53],"III":[54],"FLAURA":[55],"trial,":[56],"osimertinib":[57,218,244],"significantly":[58,82],"prolonged":[59,83],"progression-free":[60],"survival":[61,65,231],"(PFS)":[62],"and":[63,152,165,228],"overall":[64,230],"(OS)":[66],"relative":[67,236],"to":[68,110,114,119,209,237,247],"first-generation":[69,238,251],"EGFR-TKIs":[70],"patients":[72,90,164,169,193,210,260],"previously":[74,133,212,262],"untreated,":[75,134,213,263],"mutation-positive,":[77,136,215,265],"NSCLC.":[79,138,267],"also":[81],"central":[84],"nervous":[85],"system":[86],"(CNS)":[87],"PFS":[88],"CNS":[92],"metastases":[93],"at":[94],"trial":[95],"entry.":[96],"had":[98],"a":[99,124,156],"generally":[100],"manageable":[101],"tolerability":[102,242],"profile;":[103],"majority":[105],"adverse":[107],"events":[108],"considered":[109],"be":[111],"possibly":[112],"related":[113],"were":[116],"mild":[118],"moderate":[120],"severity.":[121],"represents":[123],"valuable":[125,257],"targeted":[126],"therapeutic":[127],"use":[129],"adults":[131],"Non-small":[139],"(NSCLC)":[143],"most":[146],"common":[147],"type":[148],"associated":[154],"poor":[157],"prognosis.":[158],"about":[160],"17%":[161],"Caucasian":[163],"39%":[166],"Asian":[168],"NSCLC,":[171,217],"drive":[181],"tumour":[182],"growth.":[183],"inhibitors":[187],"(EGFR-TKIs)":[188],"improve":[189],"clinical":[190],"outcomes":[191],"harbouring":[196],"first":[203],"EGFR-TKI.":[206],"When":[207],"given":[208],"delayed":[219],"disease":[220],"progression":[221],"or":[222],"death":[223],"by":[224,232],"\u2248":[225,233],"9":[226],"months":[227,235],"extended":[229],"7":[234],"EGFR-TKIs.":[239,252],"Overall,":[240],"was":[245],"similar":[246],"effective,":[256]},"counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":31},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":6}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2021-10-11T00:00:00"}